Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IV Study Assessing Efficacy of First-Line Chemotherapy With Gemcitabine in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Ineligible to FOLFIRINOX Treatment

NCT06046794 is registered in ClinicalTrials.gov with Institut Paoli-Calmettes as lead sponsor.

NCT NCT06046794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06046794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IV Study Assessing Efficacy of First-Line Chemotherapy With Gemcitabine in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Ineligible to FOLFIRINOX Treatment
Lead sponsor
Institut Paoli-Calmettes
Phase
Not applicable
Overall status
Recruiting
Start date
May 23, 2024
Completion date
November 30, 2029
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of pancreas